Evidence map›Paper›PMID 26444545›Full record

ArticleOrphanet journal of rare diseases2015

Erratum to: Establishing medical plausibility in the context of orphan medicines designation in the European Union.

Stelios Tsigkos, Segundo Mariz, Jordi Llinares, Laura Fregonese, Stiina Aarum, Frauke Naumann-Winter, Kerstin Westermark, Bruno Sepodes

Abstract readPublished Erratum
In one paragraph

Article in Orphanet journal of rare diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Stelios TsigkosOrphan Medicines Office, European Medicines Agency, 7 Westferry Circus, Canary Wharf, London, E144HB, UK. Stylianos.Tsigkos@ema.europa.eu.
Segundo MarizOrphan Medicines Office, European Medicines Agency, 7 Westferry Circus, Canary Wharf, London, E144HB, UK. segundo.mariz@ema.europa.eu.
Jordi LlinaresOrphan Medicines Office, European Medicines Agency, 7 Westferry Circus, Canary Wharf, London, E144HB, UK. jordi.llinares@ema.europa.com.
Laura FregoneseOrphan Medicines Office, European Medicines Agency, 7 Westferry Circus, Canary Wharf, London, E144HB, UK. laura.fregonese@ema.europa.eu.
Stiina AarumOrphan Medicines Office, European Medicines Agency, 7 Westferry Circus, Canary Wharf, London, E144HB, UK. stiina.aarum@ema.europa.eu.
Frauke Naumann-WinterBundesinstitut für Arzneimittel und Medizinprodukte, Kurt-Georg-Kiesinger-Allee 3, Bonn, 53175, Germany. Frauke.Naumann-Winter@bfarm.de.
Kerstin WestermarkLäkemedelsverket, Dag Hammarskjölds vägen 42, Uppsala, 75103, Sweden. kerstin.westermark@mpa.se.
Bruno SepodesResearch Institute for Medicines (iMED.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisboa, 1649-003, Portugal. bruno.sepodes@ema.europa.eu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID26444545
PMCPMC4596420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.